Search research articles
Contact Us
Filters
Showing results (41-50 of 74) with videos related to
Page
of 8
Sort By:
British Journal of Haematology
|
September 16, 2009
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
Joseph M Negri, Douglas W McMillin, Jake Delmore, et al.
Cancer Research
|
July 9, 2009
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
Douglas W McMillin, Melissa Ooi, Jake Delmore, et al.
British Journal of Haematology
|
January 13, 2011
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
Douglas W McMillin, Jake Delmore, Joseph Negri, et al.
Alternatives to Laboratory Animals : ATLA
|
June 4, 2016
Assessment of in vitro COPD models for tobacco regulatory science: Workshop proceedings, conclusions and paths forward for in vitro model use
Holger Behrsing, Hans Raabe, Joseph Manuppello, et al.
Bone Marrow Transplantation
|
September 20, 2019
Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
Curly Morris, Christian Chabannon, Tamas Masszi, et al.
Journal of Clinical Apheresis
|
June 21, 2017
UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy
Kenneth W Douglas, Maria Gilleece, Patrick Hayden, et al.
Bone Marrow Transplantation
|
November 19, 2022
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Joanna Drozd-Sokolowska, Luuk Gras, Nienke Zinger, et al.
Bone Marrow Transplantation
|
February 27, 2022
Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT
Edouard Forcade, Sylvie Chevret, Jürgen Finke, et al.
Frontiers in Immunology
|
January 7, 2022
Corrigendum: Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Johannes Schetelig, Henning Baldauf, Linda Koster, et al.
Frontiers in Immunology
|
February 5, 2021
Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Johannes Schetelig, Henning Baldauf, Linda Koster, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 74) with videos related to
Sort By:
Page
of 8
British Journal of Haematology
|
September 16, 2009
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
Joseph M Negri, Douglas W McMillin, Jake Delmore, et al.
Cancer Research
|
July 9, 2009
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
Douglas W McMillin, Melissa Ooi, Jake Delmore, et al.
British Journal of Haematology
|
January 13, 2011
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
Douglas W McMillin, Jake Delmore, Joseph Negri, et al.
Alternatives to Laboratory Animals : ATLA
|
June 4, 2016
Assessment of in vitro COPD models for tobacco regulatory science: Workshop proceedings, conclusions and paths forward for in vitro model use
Holger Behrsing, Hans Raabe, Joseph Manuppello, et al.
Bone Marrow Transplantation
|
September 20, 2019
Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
Curly Morris, Christian Chabannon, Tamas Masszi, et al.
Journal of Clinical Apheresis
|
June 21, 2017
UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy
Kenneth W Douglas, Maria Gilleece, Patrick Hayden, et al.
Bone Marrow Transplantation
|
November 19, 2022
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Joanna Drozd-Sokolowska, Luuk Gras, Nienke Zinger, et al.
Bone Marrow Transplantation
|
February 27, 2022
Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT
Edouard Forcade, Sylvie Chevret, Jürgen Finke, et al.
Frontiers in Immunology
|
January 7, 2022
Corrigendum: Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Johannes Schetelig, Henning Baldauf, Linda Koster, et al.
Frontiers in Immunology
|
February 5, 2021
Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Johannes Schetelig, Henning Baldauf, Linda Koster, et al.
Page
of 8